Facebook
Twitter
LinkedIn
Forward
Thyroid Eye Disease: Updates on Comprehensive Management (CME Symposium at NANOS 2024)
Monday, March 4, 2024
5:45 PM – 6:15 PM HST Complimentary Registration and Dinner
6:15 PM – 7:15 PM HST CME Symposium
Sheraton Waikiki Beach Resort
Moloki Room, 2nd Level
2255 Kalakaua Avenue
Honolulu, Hawaii
This symposium is not organized by NANOS. We are sharing this information as this can be of value to the NANOS annual meeting attendees and membership.
Target Audience
This educational activity is intended for neuro-ophthalmologists and other ophthalmologists treating thyroid eye disease.
Learning Objectives
After completing this activity, participants will be better able to:
- Identify diagnostic criteria that are critical for identifying patients with thyroid eye disease
- Develop individualized treatment plans for patients with thyroid eye disease according to the latest clinical data
- Review strategies to manage hyperglycemia and hearing loss in patients with thyroid eye disease receiving insulin-like growth factor 1 receptor antagonists
- Recognize the roles and responsibilities of the multidisciplinary care team in thyroid eye disease management
Faculty
 | Andrew G. Lee, MD (Co-Chair) Herb and Jean Lyman Centennial Chair in Ophthalmology Department of Ophthalmology Blanton Eye Institute Professor of Ophthalmology, Neurology, and Neurosurgery Academic Institute Full Clinical Member Research Institute Houston Methodist Weill Cornell Medical College Houston, Texas |
 | Prem S. Subramanian, MD, PhD (Co-Chair) Chief, Neuro-Ophthalmology Clifford R. and Janice N. Merrill Endowed Chair in Ophthalmology Vice Chair for Academic Affairs, Ophthalmology Professor in Ophthalmology, Neurology, and Neurosurgery Sue Anschutz-Rodgers University of Colorado Eye Center University of Colorado School of Medicine Aurora, Colorado |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Andrew G. Lee, MD, is a consultant for Alexion Pharmaceuticals, Inc, AstraZeneca, Bristol-Myers Squibb, Stoke Therapeutics, and Viridian Therapeutics, Inc; and is on the speakers bureau for Amgen Inc.
Prem S. Subramanian, MD, PhD, is a consultant for Acelyrin, Inc; is an advisory board member of Amgen Inc, GenSight Biologics, Kriya Therapeutics, and Viridian Therapeutics, Inc; and is a contracted researcher for Immunovant, Inc, Invex Therapeutics*, Neurophth Therapeutics, and Tourmaline Bio, Inc.
Peer Reviewer
Hadi Kaakour, MD, MS, was an advisory board member of Alimera Sciences*.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
* The financial relationship existed during the past 24 months but has now ended
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Amgen Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Americans With Disabilities Act 
MedEdicus fully complies with the legal requirements of the ADA and the rules and regulations thereof. Please contact info@mededicus.com with any special needs (eg, physical, dietary) prior to the program.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Fee Information
There is no fee for this educational activity.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Amgen Inc.
This CME activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. 314
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation